InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Cash-to-Debt

: No Debt ⁽¹⁾ (As of Sep. 2023)

View and export this data going back to 2010. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. InVivo Therapeutics Holdings's cash to debt ratio for the quarter that ended in Sep. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, InVivo Therapeutics Holdings could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for InVivo Therapeutics Holdings's Cash-to-Debt or its related term are showing as below:

NVIVQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.94 Med: 14.37 Max: No Debt
Current: 11.38

During the past 13 years, InVivo Therapeutics Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 4.94. And the median was 14.37.

NVIVQ's Cash-to-Debt is ranked better than
57.5% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs NVIVQ: 11.38

InVivo Therapeutics Holdings Cash-to-Debt Historical Data

The historical data trend for InVivo Therapeutics Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

InVivo Therapeutics Holdings Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

166.60

5.02

19.11

14.53

17.23

InVivo Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															10.16	17.23	15.43	14.22	No Debt

Competitive Comparison

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InVivo Therapeutics Holdings Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Cash-to-Debt falls into.

InVivo Therapeutics Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

InVivo Therapeutics Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	16.351	/	(0.396	+	0.553)
	=	17.23

InVivo Therapeutics Holdings's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

InVivo Therapeutics Holdings had no debt ⁽¹⁾.

InVivo Therapeutics Holdings (OTCPK:NVIVQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

InVivo Therapeutics Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

04I:Germany

Address

One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.invivotherapeutics.com

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

Executives

Brice Foose	10 percent owner	236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak	director	C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison	director	ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli	director, officer: CEO and CMO	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher	officer: Chief Financial Officer	C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield	director
Bob Rosenthal	director	20 NEWBURY ST, BOSTON MA 02116
Heather Hamel	officer: Chief Legal Officer and GC	ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino	officer: See Remarks	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty	officer: Chief Financial Officer	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz	officer: Interim CFO	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield	director	11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl	officer: Chief Commercial Officer	ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne	officer: Chief Medical Officer	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070